IMMO-LDRT01 TRIAL: IMMUNOMODULATORY EFFECTS OF LOW DOSE RADIATION THERAPY OF CHRONIC DEGENERATIVE AND INFLAMMATORY DISEASES (2019) Donaubauer AJ, Gryc T, Becker I, Ott OJ, Fietkau R, Gaipl U, Frey B Conference contribution THE ROLE OF THE IL-23/TH17 AXIS AS MODULATOR OF B CELL-MEDIATED (AUTO)IMMUNE RESPONSES (2019) Pfeifle R, Kittler J, Rothe T, Schett G, Krönke G Conference contribution PHYSICAL FUNCTION IN RA PATIENTS IN REMISSION UNDERGOING TAPERING AND/OR STOPPING OF DMARDS (2019) Stephan M, Tascilar K, Hagen M, Haschka J, Reiser M, Kleyer A, Manger B, et al. Conference contribution IMPORTANT ROLE OF DENDRITIC CELLS IN INFLAMMATORY ARTHRITIS (2019) Simader E, Puchner A, Saferding V, Goncalves-Alves E, Pfeifle R, Krönke G, Smolen J, Blueml S Conference contribution Possible adaptations of vascularised human skin equivalents to include rare cell populations and study fibroblast heterogeneity. Response to: ‘In search for the ideal anatomical composition of vascularised human skin equivalents for systemic sclerosis translational research: should we recruit the telocytes?’ by Manetti and Matucci-Cerinic (2019) Matei AE, Distler J Journal article, Letter Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs (2019) Matei AE, Chen CW, Kiesewetter L, Györfi AH, Li YN, Trinh-Minh T, Xu X, et al. Journal article Gout, hyperuricaemia and crystal-associated disease network (G-CAN) consensus statement regarding labels and definitions of disease states of gout (2019) Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, Gaffo AL, et al. Journal article Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual (2019) Fasano S, Riccardi A, Messiniti V, Caramaschi P, Rosato E, Maurer B, Smith V, et al. Journal article Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis (2019) Finzel S, Kraus S, Figueiredo CP, Regensburger A, Kocijan R, Rech J, Schett G Journal article Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: A proof-of-concept study (2019) Glatt S, Taylor PC, McInnes IB, Schett G, Landewe RL, Baeten D, Ionescu L, et al. Journal article